What is HC Wainwright’s Estimate for Adicet Bio Q1 Earnings?

Adicet Bio, Inc. (NASDAQ:ACET) – Equities research analysts at HC Wainwright raised their Q1 2026 EPS estimates for shares of Adicet Bio in a research note issued to investors on Monday, March 23rd. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($2.80) per share for the quarter, up from their previous estimate of ($2.91). HC Wainwright currently has a “Buy” rating and a $27.00 target price on the stock. The consensus estimate for Adicet Bio’s current full-year earnings is ($1.39) per share. HC Wainwright also issued estimates for Adicet Bio’s Q2 2026 earnings at ($2.87) EPS, Q3 2026 earnings at ($2.93) EPS, Q4 2026 earnings at ($2.99) EPS and FY2026 earnings at ($11.58) EPS.

Several other analysts have also weighed in on ACET. Guggenheim decreased their price objective on Adicet Bio from $128.00 to $100.00 and set a “buy” rating on the stock in a report on Friday, March 13th. Canaccord Genuity Group set a $18.00 target price on Adicet Bio and gave the company a “buy” rating in a research note on Tuesday, January 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adicet Bio in a research report on Tuesday, January 27th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $56.25.

Adicet Bio Stock Up 1.8%

Shares of ACET opened at $6.81 on Wednesday. The stock’s 50-day moving average price is $7.43 and its 200 day moving average price is $9.80. The firm has a market capitalization of $65.38 million, a price-to-earnings ratio of -0.38 and a beta of 1.56. Adicet Bio has a 12-month low of $6.41 and a 12-month high of $17.44.

Adicet Bio (NASDAQ:ACET) last released its earnings results on Thursday, March 12th. The company reported ($2.94) earnings per share for the quarter, beating the consensus estimate of ($3.23) by $0.29.

Institutional Investors Weigh In On Adicet Bio

A number of hedge funds and other institutional investors have recently bought and sold shares of ACET. Goldman Sachs Group Inc. raised its position in Adicet Bio by 1.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 3,816,556 shares of the company’s stock valued at $2,882,000 after purchasing an additional 63,691 shares during the last quarter. Two Sigma Investments LP grew its holdings in shares of Adicet Bio by 66.6% during the third quarter. Two Sigma Investments LP now owns 854,568 shares of the company’s stock worth $692,000 after purchasing an additional 341,761 shares during the last quarter. Franklin Resources Inc. acquired a new stake in shares of Adicet Bio in the fourth quarter valued at $5,276,000. Citadel Advisors LLC increased its stake in shares of Adicet Bio by 19.8% in the third quarter. Citadel Advisors LLC now owns 583,948 shares of the company’s stock valued at $473,000 after buying an additional 96,342 shares in the last quarter. Finally, Wealthedge Investment Advisors LLC raised its holdings in shares of Adicet Bio by 37.4% in the second quarter. Wealthedge Investment Advisors LLC now owns 313,108 shares of the company’s stock valued at $191,000 after buying an additional 85,307 shares during the last quarter. 83.89% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Adicet Bio

Here are the key news stories impacting Adicet Bio this week:

• Positive Sentiment: HC Wainwright raised near-term and full-year 2026 EPS forecasts (Q1–Q4 and FY), trimming projected losses (e.g., Q1 est. now ($2.80) vs prior ($2.91); FY2026 now ($11.58) vs ($12.17)) and reiterated a “Buy” rating with a $27 price target — signals improved analyst sentiment and a large implied upside versus the current share price. MarketBeat HC Wainwright Coverage
• Positive Sentiment: Zacks upgraded ACET to a Zacks Rank #2 (Buy), citing improving earnings prospects — upgrades from recognized research services can attract buying interest and short-term momentum. Adicet Bio (ACET) Upgraded to Buy: Here’s Why
• Neutral Sentiment: Reported short-interest data for March shows anomalous “0 shares” and NaN changes across multiple filings — the numbers appear unreliable or misreported, so there is no clear evidence of elevated short pressure based on the available data. (Monitor future filings for corrected short-interest figures.)
• Negative Sentiment: An AmericanBankingNews headline framed HC Wainwright’s coverage as a “pessimistic forecast” for ACET stock price — conflicting media spin can add volatility even when analyst estimates are being trimmed toward smaller losses. HC Wainwright Issues Pessimistic Forecast for Adicet Bio (NASDAQ:ACET) Stock Price

About Adicet Bio

Adicet Bio, Inc (NASDAQ: ACET) is a clinical‐stage biotechnology company specializing in the development of off‐the‐shelf, allogeneic gamma delta (γδ) T cell therapies for oncology and autoimmune disorders. The company’s proprietary platform enables the genetic engineering of γδ T cells with chimeric antigen receptors (CARs) and other molecular modifications to enhance tumor targeting, expansion, and persistence. By leveraging the innate tumor-recognition properties of γδ T cells, Adicet seeks to overcome the manufacturing and safety challenges associated with autologous cell therapies.

Adicet’s lead product candidate, ADI-001, is a CAR‐engineered allogeneic γδ T cell therapy directed against CD20 for the treatment of relapsed or refractory B-cell malignancies.